Terms: = Melanoma AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Treatment
166 results:
1. miR-876-3p is a tumor suppressor on 9p21 that is inactivated in melanoma and targets ERK.
Bezrookove V; Khan I; Bhattacharjee A; Fan J; Jones R; Sharma A; Nosrati M; Desprez PY; Salomonis N; Shi Y; Dar A; Kashani-Sabet M
J Transl Med; 2024 Aug; 22(1):758. PubMed ID: 39138582
[TBL] [Abstract] [Full Text] [Related]
2. Biphasic co-detection of melanoma aneuploid tumor cells and tumor endothelial cells in guidance of specifying the field cancerized surgical excision margin and administering immunotherapy.
Fu Z; Zhang L; Chen R; Zhan J; Zhong J; Zheng W; Zou J; Wang P; Deng X; Lin AY; Wang DD; Lin PP; He R
Cancer Lett; 2024 Aug; 598():217099. PubMed ID: 38971491
[TBL] [Abstract] [Full Text] [Related]
3. Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma.
Connell E; Gerard É; Oules B; Brunet-Possenti F; Lamoureux A; Bonnefille H; Mary-Prey S; Carrasquilla A; Mouret S; Kramkimel N; Lesage C; Stoebner PE; Bartoli A; Monestier S; Correard F; Gros A; Jeanson A; Ouafik L; Gaudy-Marqueste C; Tomasini P; Charles J; Amini-Adle M; Malissen N
Oncologist; 2024 Sep; 29(9):e1180-e1188. PubMed ID: 38761384
[TBL] [Abstract] [Full Text] [Related]
4. The mechanisms behind the dual role of long non-coding RNA (lncRNA) metastasis suppressor-1 in human tumors: Shedding light on the molecular mechanisms.
Abdullaev B; Alsaab HO; Hjazi A; Alkhafaji AT; Alawadi AH; Hamzah HF
Pathol Res Pract; 2024 Apr; 256():155189. PubMed ID: 38452581
[TBL] [Abstract] [Full Text] [Related]
5. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma.
Jagirdar K; Portuallo ME; Wei M; Wilhide M; Bravo Narula JA; Robertson BM; Alicea GM; Aguh C; Xiao M; Godok T; Fingerman D; Brown GS; Herlyn M; Elad VM; Guo X; Toska E; Zabransky DJ; Wubbenhorst B; Nathanson KL; Kwatra S; Goyal Y; Ji H; Liu Q; Rebecca VW
Oncogene; 2024 Feb; 43(6):395-405. PubMed ID: 38066089
[TBL] [Abstract] [Full Text] [Related]
6. The Assessment of Anti-melanoma Potential of Tigecycline-Cellular and Molecular Studies of Cell Proliferation, Apoptosis and Autophagy on Amelanotic and Melanotic melanoma Cells.
Rok J; Kowalska J; Rzepka Z; Stencel D; Skorek A; Banach K; Wrześniok D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371034
[TBL] [Abstract] [Full Text] [Related]
7. Role of Sleep Apnea and Long-Term CPAP treatment in the Prognosis of Patients With melanoma: A Prospective Multicenter Study of 443 Patients.
Gómez-Olivas JD; Campos-Rodriguez F; Nagore E; Martorell A; García-Rio F; Cubillos C; Hernandez L; Bañuls J; Arias E; Ortiz P; Cabriada V; Gardeazabal J; Montserrat JM; Carrera C; Masa JF; Gomez de Terreros J; Abad J; Boada A; Mediano O; Castillo-Garcia M; Chiner E; Landete P; Mayos M; Fortuna A; Barbé F; Sanchez-de-la-Torre M; Cano-Pumarega I; Perez-Gil A; Gomez-Garcia T; Cullen D; Somoza M; Formigon M; Aizpuru F; Oscullo G; Garcia-Ortega A; Almendros I; Farré R; Gozal D; Martinez-Garcia MA
Chest; 2023 Dec; 164(6):1551-1559. PubMed ID: 37348828
[TBL] [Abstract] [Full Text] [Related]
8. The MDM2 Inhibitor Navtemadlin Arrests Mouse melanoma Growth
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Cancer Res Commun; 2022 Sep; 2(9):1075-1088. PubMed ID: 36922937
[TBL] [Abstract] [Full Text] [Related]
9. Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma.
Frias A; Di Leo L; Antoranz A; Nazerai L; Carretta M; Bodemeyer V; Pagliuca C; Dahl C; Claps G; Mandelli GE; Andhari MD; Pacheco MP; Sauter T; Robert C; Guldberg P; Madsen DH; Cecconi F; Bosisio FM; De Zio D
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36868570
[TBL] [Abstract] [Full Text] [Related]
10. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract] [Full Text] [Related]
11. Locally advanced choroidal melanoma with favorable molecular prognosis - case report.
Bălăşoiu AT; Ştefănescu-Dima AŞ; Bălăşoiu M; Ciurea RN; Muraru A; Dan AO; Simionescu CE
Rom J Morphol Embryol; 2022; 63(4):645-652. PubMed ID: 36808200
[TBL] [Abstract] [Full Text] [Related]
12. Ezrin accelerates breast cancer liver metastasis through promoting furin-like convertase-mediated cleavage of Notch1.
Chen M; Pan Y; Liu H; Ning F; Lu Q; Duan Y; Gan X; Lu S; Hou H; Zhang M; Tian Y; Lash GE
Cell Oncol (Dordr); 2023 Jun; 46(3):571-587. PubMed ID: 36580262
[TBL] [Abstract] [Full Text] [Related]
13. Therapeutic Strategies for Targeting cdkn2a Loss in melanoma.
Kreuger IZM; Slieker RC; van Groningen T; van Doorn R
J Invest Dermatol; 2023 Jan; 143(1):18-25.e1. PubMed ID: 36123181
[TBL] [Abstract] [Full Text] [Related]
14. Molecular Features of Preinvasive and Invasive Vulvar Neoplasms.
Deb PQ; Heller DS
J Low Genit Tract Dis; 2023 Jan; 27(1):40-46. PubMed ID: 36083687
[TBL] [Abstract] [Full Text] [Related]
15. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER
Palafox M; Monserrat L; Bellet M; Villacampa G; Gonzalez-Perez A; Oliveira M; Brasó-Maristany F; Ibrahimi N; Kannan S; Mina L; Herrera-Abreu MT; Òdena A; Sánchez-Guixé M; Capelán M; Azaro A; Bruna A; Rodríguez O; Guzmán M; Grueso J; Viaplana C; Hernández J; Su F; Lin K; Clarke RB; Caldas C; Arribas J; Michiels S; García-Sanz A; Turner NC; Prat A; Nuciforo P; Dienstmann R; Verma CS; Lopez-Bigas N; Scaltriti M; Arnedos M; Saura C; Serra V
Nat Commun; 2022 Sep; 13(1):5258. PubMed ID: 36071033
[TBL] [Abstract] [Full Text] [Related]
16. In silico-prediction of chloroquine as a multi-targeted drug against cdkn2a signaling network associated with cutaneous malignant melanoma.
Jan Z; Aqeel M; Munir A; Saeed A; Sadia H; Kalsoom S; Nadeem T; Bashir Z; Awan L; Ud Din S; Muhammad Ali G
Pak J Pharm Sci; 2022 May; 35(3):731-739. PubMed ID: 35791470
[TBL] [Abstract] [Full Text] [Related]
17. Variable Genomic Landscapes of Advanced melanomas with Heavy Pigmentation.
Huang RSP; Tse JY; Harries L; Graf RP; Lin DI; Murugesan K; Hiemenz MC; Parimi V; Janovitz T; Decker B; Severson E; Levy MA; Ramkissoon SH; Elvin JA; Ross JS; Williams EA
Oncologist; 2022 Aug; 27(8):655-662. PubMed ID: 35552752
[TBL] [Abstract] [Full Text] [Related]
18. Mechanistic Translation of melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions.
Massimino M; Stella S; Micale G; Motta L; Pavone G; Broggi G; Piombino E; Magro G; Soto Parra HJ; Manzella L; Vigneri P
Cancer Genomics Proteomics; 2022; 19(3):350-361. PubMed ID: 35430568
[TBL] [Abstract] [Full Text] [Related]
19. The EORTC protocol for sentinel lymph node biopsy (SLNB) reveals a high number of nodal nevi and a strong association with nevus-associated melanoma.
Ricci C; Dika E; Lambertini M; Ambrosi F; Chiarucci F; Chillotti S; Fiorentino M; Fabbri E; Tassone D; Veronesi G; Tartari F; Corti B
Pathol Res Pract; 2022 May; 233():153805. PubMed ID: 35361504
[TBL] [Abstract] [Full Text] [Related]
20. Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant melanoma.
Schuler M; Zimmer L; Kim KB; Sosman JA; Ascierto PA; Postow MA; De Vos FYFL; van Herpen CML; Carlino MS; Johnson DB; Berking C; Reddy MB; Harney AS; Berlin JD; Amaria RN
Clin Cancer Res; 2022 Jul; 28(14):3002-3010. PubMed ID: 35294522
[TBL] [Abstract] [Full Text] [Related]
[Next]
